SGB-9768 / Sanegene Bio - LARVOL DELTA

Safety and Pharmacodynamics of SGB-9768, an siRNA Targeting Complement C3 in Healthy Volunteers (KIDNEY WEEK 2025) - "Figure 1. Measures of serum complement C3 level (a), Wieslab® AP (b), Wieslab® CP (c) in healthy volunteers."

Clinical • PK/PD data • Complement-mediated Rare Disorders • Glomerulonephritis • IgA Nephropathy • Infectious Disease • Meningococcal Infections • Nephrology • Pneumococcal Infections • Renal Disease

A multi-center, open-label, Phase II study to evaluate the efficacy and safety of SGB-9768 in patients with primary IgAropathy, C3 glomerulopathy, and immune complex-mediated membranoproliferative glomerulonephritis. (ChiCTR) - P2 | N=38 | Not yet recruiting | Sponsor: Peking University First Hospital; Peking University First Hospital

New P2 trial • Complement-mediated Rare Disorders • Glomerulonephritis • IgA Nephropathy • Lupus Nephritis • Nephrology • Renal Disease

A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases (clinicaltrials.gov) - P2 | N=38 | Not yet recruiting | Sponsor: Suzhou Sanegene Bio Inc.

New P2 trial • Complement-mediated Rare Disorders • Glomerulonephritis • IgA Nephropathy • Lupus Nephritis • Nephrology • Renal Disease

SGB-9768-002: A Study of SGB-9768 in Adult Healthy Volunteers (clinicaltrials.gov) - P1 | N=37 | Active, not recruiting | Sponsor: Suzhou Sanegene Bio Inc. | Not yet recruiting ➔ Active, not recruiting

Enrollment closed

A First-in-Human Study of SGB-9768 in Healthy Volunteers (ANZCTR) - P1 | N=36 | Recruiting | Sponsor: Sanegene Bio New Zealand Ltd | Not yet recruiting ➔ Recruiting | Initiation date: May 2024

Enrollment open • Trial initiation date

SGB-9768-002: A Study of SGB-9768 in Adult Healthy Volunteers (clinicaltrials.gov) - P1 | N=37 | Not yet recruiting | Sponsor: Suzhou Sanegene Bio Inc.

New P1 trial